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Methods: Patients who received l-OHP were eligible for this phase I study. Patients
who have neuropathy or skin lesion on their hands were excluded. Patients who have
experienced l-OHP regimens before were also excluded. Wrist and hand size were
measured and appropriate size of gloves was selected. The pressure of hands is esti-
mated as 20-33 hPa.Patients start to wear the gloves on both hands, from 30 min before
the injection of l-OHP until 30 min after the injection. Peripheral neuropathy of both
hands was evaluated at each treatment cycle using common terminology criteria for
adverse events (CTCAE) version 4.0.
Results: Between October 2017 and August 2018, fourteen patients (median age 66
years [range 39– 79years], 7 male and 7 female) were enrolled and were evaluated. No
patients withdrew from this study. No safety concerns were identified for any safety var-
iables assessed during the trial. CTCAE grade 2 or higher sensory PN was observed in
four (28.6%) patients. The average time until grade1 or more neuropathy appeared was
44.0 days and average dose of l-OHP was 330 mg. Two patients experienced severe PN
in their feet and/or throat and mild PN in their hands.
Conclusion: Compression therapy by the new gloves had no safety concerns, demon-
strating a profile favorable for further development for the prevention of oxaliplatin-
induced PN.
P 288 The role of sidedness in second-line therapy for RAS wild-type
colorectal cancer: a network meta-analysis (NMA)
D Basile1, G Pelizzari2, P Di Nardo3, C Corvaja2, E Ongaro4, S Garattini2, L Gerratana5,
C Lisanti5, B Michele5, L Bortot5, S Buriolla5, M Garutti6, G Curtolo2, M Bonotto7, L Da
Ros4, E Torrisi4, G Miolo4, G Cardellino8, N Pella8, A Buonadonna9, G Aprile10, F Puglisi2
1Department of Medicine (DAME), University of Udine, 33100 Udine, Italy; , aviano, Italy,
2Department of Medicine (DAME), University of Udine, 33100 Udine, Italy; Dipartimento
di Oncologia Clinica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081
Aviano, Italy, aviano, Italy, 3Dipartimento di Oncologia Clinica, Centro di Riferimento
Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy, Rome, Italy, 4Dipartimento di
Oncologia Clinica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081
Aviano, Italy, aviano, Italy, 5Department of Medicine (DAME), University of Udine, 33100
Udine, Italy; Dipartimento di Oncologia Clinica, Centro di Riferimento Oncologico di
Aviano (CRO), IRCCS, 33081 Aviano, Italy, Aviano, Italy, 6U.O.C Oncologia, Fondazione
Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy, aviano, Italy,
7Department of Oncology, University and General Hospital, Udine, Italy, Udine, Italy,
8Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della
Misericordia, Udine, Italy, 9Dipartimento di Oncologia Clinica, Centro di Riferimento
Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy, Aviano, Italy, 10Department of
Oncology, San Bortolo General Hospital, Vicenza (VI), IT, Vicenza, Italy
Introduction: Primary tumor location (PTL) is a prognostic and potentially predictive
factor in metastatic colorectal cancer (mCRC). Intriguingly, post-hoc analyses sug-
gested limited benefit from the upfront use of anti-epidermal growth factor receptor
antibodies (EGFR) in patients with RAS wild-type (wt) right-sided tumors. While the
predictive impact of PTL on clinical outcome after first-line treatment in RAS wt
mCRC is uncertain, the lack of head-to-head randomized controlled trials (RCTs)
according to sidedness complicate the optimal treatment choice. We conducted a sys-
tematic review and NMA to evaluate the role of sidedness on the efficacy of second-line
treatments.
Methods: The systematic review included all phase II/III randomized clinical trials
(RCTs) published or presented at international conferences comparing different sec-
ond-line treatments for RAS wt mCRC. Only trials with RAS wt mCRC were included.
We performed a random-effect frequentist NMA to evaluate indirect comparisons of
regimens including anti-EGFR or anti-vascular endothelial growth factor antibodies
(VEGF) based, CT alone or best supportive care (BSC). Progression-free survival (PFS)
and Overall Survival (OS) were the outcomes of interest. Analyses were performed for
all patients on a trial-based level, regardless of or according to sidedness, when data
were available. Surface under the cumulative ranking value (SUCRA) was applied to
rank the effect size of treatments.
Results: Overall, 11 RCTs (3,384 patients) were included. In RAS wt patients, PFS was
improved with anti-VEGF (HR¼ 0.63, 95% CI 0.52-0.76) and anti-EGFR (HR¼ 0.77,
95% CI 0.64-0.91) vs CT, regardless of side. Despite the lack of a statistically proven
PFS superiority of anti-VEGF vs anti-EGFR (HR¼ 0.82, 95% CI 0.66-1.01), anti-VEGF
showed the highest likelihood of being ranked as the best treatment in terms of PFS
according to SUCRA (98.8% and 67.7% respectively). Conversely, anti-VEGF
improved OS compared to both CT (HR¼ 0.72, 95% CI 0.63-0.83) and anti-EGFR
(HR¼ 0.77, 95% CI 0.66-0.88). In 5 RCTs sidedness data were available. In patients
with right-sided mCRC no improvement in OS or PFS was observed with either bio-
logic added to CT vs CT alone. In patients with left-sided mCRC an improvement in
PFS was observed with anti-VEGF vs both CT (HR¼ 0.51, 95% CI 0.33-0.80) and anti-
EGFR (HR¼ 0.59, 95% CI 0.40-0.88). SUCRA favored anti-VEGF for PFS (99.8% and
63.5% respectively), while no improvement in OS was observed.
Conclusion: Through indirect comparisons, second-line regimens with CT and anti-
VEGF or anti-EGFR improved PFS in RAS wt mCRC patients. Anti-VEGF based ther-
apy appeared to have higher chances to have better efficacy results according to SUCRA
compared to the others. Anti-VEGF could be considered the best second-line choice in
left mCRC (specifically for patients who have received upfront EGFR-inhibitors), while
no combination provided significant efficacy improvement for right-sided mCRC over
CT alone.
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Introduction: Cancer-related fatigue (CRF) is a distressing, persistent, subjective sense
of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or
cancer treatment that is not proportional to recent activity and interferes with usual
functioning. Existing findings point out that cancer patients are greatly impacted by
CRF; however, the condition is often underdiagnosed and therapeutic management is
challenging. A better characterization of CRF, together with identifying which subjec-
tive aspect of a patient’s life is most affected could lead to better management, especially
in the case of gastric cancer patients that are often elderly and in most cases have secon-
dary anemia.
Methods: All gastric cancer patients undergoing systemic treatment in the Regional
Institute of Oncology Iasi in October 2018 were asked to complete the EORTC QLQ-
FA12 questionnaire, a multidimensional instrument measuring cancer-related fatigue.
Fatigue-related data was analyzed and a mean fatigue score was calculated for each
patient (100/3*(mean score of the first ten items – 1)). Afterward, the three aspects of
fatigue assessed by the questionnaire – physical, cognitive and emotional – were each
quantified separately. For each patient, several other data related to individual charac-
teristics, tumor biology and treatment were collected from their medical charts and cor-
related with the reported fatigue levels.
Results: 61 patients answered the questionnaire. Mean age was 60.63611.61 years,
ranging from 32 to 84 years. Male: female ratio was 1.9:1. ECOG performance status
was 0 or 1 in most cases (65.6%). Almost half of the respondents were receiving plati-
num-based neoadjuvant or adjuvant chemotherapy (42.6%) and almost 15% had
received two or more previous lines of treatment for stage IV disease (a median of four
chemotherapy cycles, ranging between 1 and 14). 45.9% of the patients had a history of
gastric surgery – total or subtotal gastrectomy. At the time of the survey, 50.8% of the
patients had grade I anemia and 14.7% had grade II anemia, although this did not cor-
relate with fatigue severity. Overall fatigue was rated at 27.04% (out of a maximum of
100), with a minimum of 3.33% and a maximum of 86.66%. Of the three aspects of
fatigue, gastric cancer patients rated physical fatigue as the most important component
of their asthenia, with values ranging between 6.67% and 93.32% and a mean physical
fatigue score of 37.59%. In contrast, both emotional and cognitive fatigue were most
often rated as rare occurrences, with 41% of patients declaring they do not experience
emotional fatigue and 67.2% of patients declaring they do not experience cognitive
fatigue.
Conclusion: Cancer-related fatigue is an important and often underdiagnosed symp-
tom in oncology patients. The EORTC QLQ-FA12 is a new instrument validated for
cancer patients, easy to apply and useful for assessing the different dimensions of
fatigue, which in turn can help individualize fatigue management. In our group, the
physical component of fatigue seems to be the most important source of discomfort
and palliative interventions should also take into account improving physical endur-
ance when possible.
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Introduction: Median age of pancreatic adenocarcinoma (PDAC) is 71 years. The inci-
dence of PDAC among young individuals is rising. Little is known about the clinicopa-
thological features and outcome of a subgroup of younger adults with PDAC.
Methods: Total of 516 patients with PDAC were identified using the institutional
tumor registry database for years 2013-2017. Patients were categorized as young (50
years) or older (, 70 years). Analyses were performed on the entire cohort for gender,
race, year of diagnosis and the presence of metastasis at diagnosis. Differences in cate-
gorical variables were assessed using Chi-square, and differences in continuous varia-
bles were assessed using Wilcoxon tests. Overall time of survival was assessed using
Kaplan-Meier curves and Cox Proportional Hazards models. To assess differences in
disease characteristics, treatment patterns, and outcomes of younger and older patients,
propensity analysis was used to match older patients to younger patients, based on sex,
race, year of diagnosis, and presence of metastatic disease at diagnosis. Somatic/germ-
line data was not available for this cohort of patients.
Results: Total of 73 younger (median age 46; range, 32-50) and 443 older (median age
77; range 70-97) patients with PDAC were retrospectively studied. No statistically sig-
nificant differences were seen between the two groups with respect to the distribution
of race (p¼ 0.1), gender (p¼ 0.08), year of diagnosis (p¼ 0.15), or metastatic disease
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